2013

1. Biochemical markers of bone turnover and clinical outcome in patients with renal cell and bladder carcinoma with bone metastases following treatment with zoledronic acid: The TUGAMO study

   British Journal of Cancer, Vol. 109, Núm. 1, pp. 121-130

2. Usefulness of bone turnover markers as predictors of mortality risk, disease progression and skeletal-related events appearance in patients with prostate cancer with bone metastases following treatment with zoledronic acid: TUGAMO study

   British Journal of Cancer, Vol. 108, Núm. 12, pp. 2565-2572